Jundishapur Journal of Microbiology

Published by: Kowsar

Evaluation of Ciprofloxacin (gyrA, parC Genes) and Tetracycline (tetB Gene) Resistance in Nosocomial Acinetobacter baumannii Infections

Jamileh Nowroozi 1 , Abbas Akhavan Sepahi 1 , Lida Tahmasebinejad Kamarposhti 1 , * , Roya Razavipour 1 and Flor Mazhar 1
Authors Information
1 Faculty of Biological Science, Islamic Azad University, North-Tehran Branch, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: February 01, 2014, 7 (2); e8976
  • Published Online: February 1, 2014
  • Article Type: Research Article
  • Received: November 16, 2012
  • Revised: January 22, 2013
  • Accepted: January 30, 2013
  • DOI: 10.5812/jjm.8976

To Cite: Nowroozi J, Akhavan Sepahi A, Tahmasebinejad Kamarposhti L, Razavipour R, Mazhar F. Evaluation of Ciprofloxacin (gyrA, parC Genes) and Tetracycline (tetB Gene) Resistance in Nosocomial Acinetobacter baumannii Infections, Jundishapur J Microbiol. 2014 ; 7(2):e8976. doi: 10.5812/jjm.8976.

Abstract
Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996; 23(3): 538-42[PubMed]
  • 2. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother. 2000; 44(6): 1556-61[PubMed]
  • 3. Singh B, Mitchison DA. Bactericidal activity of streptomycin and isoniazid against tubercle bacilli. Br Med J. 1954; 1(4854): 130-2[PubMed]
  • 4. Malek Nejad P, Arjmand M, Sotoudenia AH, Mansourirad AR. Jautz summary and medical microbiology tests. 2006;
  • 5. Ling TK, Ying CM, Lee CC, Liu ZK. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong. Med Princ Pract. 2005; 14(5): 338-41[DOI][PubMed]
  • 6. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12(1): 147-79[PubMed]
  • 7. Sheldon AT. Antiseptic “resistance”: real or perceived threat? Clin infect Dis. 2005; 40(11): 1650-6
  • 8. 2009;
  • 9. Performance Standards for Antimicrobial Susceptibility testing . Clinical and laboratory standards institute, 19th informational supplement (M100-S19). 2007;
  • 10. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther. 2003; 1(4): 667-83[PubMed]
  • 11. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med. 2009; 360(5): 439-43[DOI][PubMed]
  • 12. Weaver RE, Actis LA. Identification of Acinetobacter species. J Clin Microbiol. 1994; 32(7): 1833[PubMed]
  • 13. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006; 50(12): 4114-23[DOI][PubMed]
  • 14. Srinivasan VB, Rajamohan G, Pancholi P, Stevenson K, Tadesse D, Patchanee P, et al. Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA. Ann Clin Microbiol Antimicrob. 2009; 8: 21[DOI][PubMed]
  • 15. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008; 52(11): 3837-43[DOI][PubMed]
  • 16. Vila J, Ruiz J, Goni P, Marcos A, Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 1995; 39(5): 1201-3[PubMed]
  • 17. Vila J, Ruiz J, Goni P, Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother. 1997; 39(6): 757-62[PubMed]
  • 18. Seward RJ, Towner KJ. Molecular epidemiology of quinolone resistance inAcinetobacterspp. Clin Microbiol Infect. 1998; 4(5): 248-54[DOI]
  • 19. Hamouda A, Amyes SG. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Chemother. 2004; 54(3): 695-6[DOI][PubMed]
  • 20. Lee JK. Genetic analysis of fluoroquinolone-resistant Acinetobacter baumannii isolates from Korea. European Congress of Clinica. 2007;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments